PURPOSE: The osteoprotogerin/receptor activator of NF-kappa β/receptor activator of NF-kappa β ligand (OPG/RANK/RANKL) pathway plays a critical role in bone remodeling. This study investigated associations between serum levels of OPG, soluble RANKL (sRANKL), and the ratio of OPG/sRANKL to risk of incident hip fracture. METHODS: A nested case-control study was conducted among postmenopausal, Caucasian women aged 50-79 at baseline (1993-1998), followed for hip fracture through March 2005 in the Women's Health Initiative Observational Study. 400 incident hip fracture cases were selected and individually matched to 400 controls with no prior fracture or incident hip fracture. Matching factors were baseline age, enrollment date and hormone therapy (HT) exposure. Baseline serum OPG and sRANKL levels were measured using high sensitivity ELISA. Odds ratios were computed for quartiles of each biomarker adjusting for matching factors and hip fracture risk factors. RESULTS: Serum OPG was significantly associated with older age, low physical activity and poorer physical function in control women. sRANKL was inversely associated with total calcium intake in control women, but not associated with age or other fracture risk factors. The odds ratio for hip fracture comparing the highest to lowest quartiles of OPG was 2.28 (95% confidence interval (CI), 1.45-3.61) after adjusting for the matching variables (p-value for linear trend <0.001), and 1.87 (95% CI, 1.15-3.04; p for linear trend=0.02) after adjusting for self-rated health status, physical activity and physical functioning. No significant associations between sRANKL or the ratio of OPG/sRANKL and hip fracture risk were observed. CONCLUSION: Serum OPG levels were independently associated with a nearly twofold increased risk of hip fracture in postmenopausal women.
PURPOSE: The osteoprotogerin/receptor activator of NF-kappa β/receptor activator of NF-kappa β ligand (OPG/RANK/RANKL) pathway plays a critical role in bone remodeling. This study investigated associations between serum levels of OPG, soluble RANKL (sRANKL), and the ratio of OPG/sRANKL to risk of incident hip fracture. METHODS: A nested case-control study was conducted among postmenopausal, Caucasian women aged 50-79 at baseline (1993-1998), followed for hip fracture through March 2005 in the Women's Health Initiative Observational Study. 400 incident hip fracture cases were selected and individually matched to 400 controls with no prior fracture or incident hip fracture. Matching factors were baseline age, enrollment date and hormone therapy (HT) exposure. Baseline serum OPG and sRANKL levels were measured using high sensitivity ELISA. Odds ratios were computed for quartiles of each biomarker adjusting for matching factors and hip fracture risk factors. RESULTS: Serum OPG was significantly associated with older age, low physical activity and poorer physical function in control women. sRANKL was inversely associated with total calcium intake in control women, but not associated with age or other fracture risk factors. The odds ratio for hip fracture comparing the highest to lowest quartiles of OPG was 2.28 (95% confidence interval (CI), 1.45-3.61) after adjusting for the matching variables (p-value for linear trend <0.001), and 1.87 (95% CI, 1.15-3.04; p for linear trend=0.02) after adjusting for self-rated health status, physical activity and physical functioning. No significant associations between sRANKL or the ratio of OPG/sRANKL and hip fracture risk were observed. CONCLUSION: Serum OPG levels were independently associated with a nearly twofold increased risk of hip fracture in postmenopausal women.
Authors: J David Curb; Anne McTiernan; Susan R Heckbert; Charles Kooperberg; Janet Stanford; Michael Nevitt; Karen C Johnson; Lori Proulx-Burns; Lisa Pastore; Michael Criqui; Sandra Daugherty Journal: Ann Epidemiol Date: 2003-10 Impact factor: 3.797
Authors: Jennifer Hays; Judith K Ockene; Robert L Brunner; Jane M Kotchen; JoAnn E Manson; Ruth E Patterson; Aaron K Aragaki; Sally A Shumaker; Robert G Brzyski; Andrea Z LaCroix; Iris A Granek; Barbara G Valanis Journal: N Engl J Med Date: 2003-03-17 Impact factor: 91.245
Authors: Ki Won Oh; Eun Jung Rhee; Won Young Lee; San Woo Kim; Eun Sook Oh; Ki Hyun Baek; Moo Il Kang; Moon Gi Choi; Hyung Joon Yoo; Sung Woo Park Journal: Clin Endocrinol (Oxf) Date: 2004-08 Impact factor: 3.478
Authors: Georg Schett; Stefan Kiechl; Kurt Redlich; Friedrich Oberhollenzer; Siegfried Weger; Georg Egger; Agnes Mayr; Josef Jocher; Qingbo Xu; Peter Pietschmann; Steven Teitelbaum; Josef Smolen; Johann Willeit Journal: JAMA Date: 2004-03-03 Impact factor: 56.272
Authors: S Khosla; H M Arrighi; L J Melton; E J Atkinson; W M O'Fallon; C Dunstan; B L Riggs Journal: Osteoporos Int Date: 2002-05 Impact factor: 4.507
Authors: JoAnn E Manson; Philip Greenland; Andrea Z LaCroix; Marcia L Stefanick; Charles P Mouton; Albert Oberman; Michael G Perri; David S Sheps; Mary B Pettinger; David S Siscovick Journal: N Engl J Med Date: 2002-09-05 Impact factor: 91.245
Authors: Song Yao; Yali Zhang; Li Tang; Janise M Roh; Cecile A Laurent; Chi-Chen Hong; Theresa Hahn; Joan C Lo; Christine B Ambrosone; Lawrence H Kushi; Marilyn L Kwan Journal: Breast Cancer Res Treat Date: 2016-12-03 Impact factor: 4.872
Authors: Daniela F Cardoso; Elisa A Marques; Diogo V Leal; Aníbal Ferreira; Luke A Baker; Alice C Smith; João L Viana Journal: BMC Nephrol Date: 2020-08-08 Impact factor: 2.388